Bioprocess Automation Market to Reach $13.6B
The global market for bioprocess automation and control software is projected to reach $13.59 billion by 2032. North America is expected to lead this expansion, holding a 42.8% market share. The growth is reportedly driven by the increasing need for scalable, compliant, and integrated digital solutions in biologics and gene therapy manufacturing.
- Key market players like Merck KGaA, Sartorius, Danaher, and Thermo Fisher are central to the innovation in this sector, alongside increasing investments in advanced biologics manufacturing from governments. The adoption of single-use systems and modular platforms is also a significant factor, offering the scalability and flexibility required for personalized medicine. - The implementation of Industry 4.0 principles is advancing biomanufacturing, with digital twins—virtual replicas of physical processes—being used to simulate, monitor, and optimize production in real-time without disrupting actual operations. These technologies, combined with AI and the Internet of Things (IoT), enhance predictive maintenance, process control, and regulatory compliance. - A major challenge in scaling up bioprocess automation is data management, as information is often fragmented across various systems like LIMS, Excel, and handwritten logs, creating data silos. Establishing a comprehensive data governance strategy is crucial to standardize and integrate this data for effective analysis and regulatory compliance. - In cell and gene therapy, automation is critical for moving from manual, variable processes to standardized, scalable manufacturing, which is necessary for commercial viability. Fully closed and integrated automated platforms are being developed to minimize contamination, reduce human error, and lower manufacturing costs by potentially eliminating the need for clean rooms. - For viral vector production, a key component in many gene therapies, automation can be applied at nearly every stage, from single-cell seeding to final assays, allowing for continuous 24/7 operation and reducing contamination risks. However, low yields and scaling up production from laboratory to commercial quantities while maintaining consistency remain significant hurdles. - Artificial intelligence and machine learning are being leveraged to reduce development timelines and improve predictability, with some companies reporting a 30-50% reduction in experimental runs and a significant decrease in batch failures. These technologies analyze large datasets to optimize parameters, predict outcomes, and automate process controls, leading to higher yields and faster scale-up. - The Contract Development and Manufacturing Organization (CDMO) sector is experiencing a shift, with sponsors increasingly seeking strategic partners who can offer innovation and digital capabilities, not just transactional manufacturing services. After a period of reduced investment, the biotech funding climate is expected to improve in 2026, which will likely reactivate delayed development programs and increase outsourcing to CDMOs. - Regulatory bodies like the FDA are showing support for innovations such as continuous manufacturing, which requires robust automation and real-time process monitoring. This alignment, along with the increasing number of personalized medicines gaining approval, is a significant driver for the adoption of advanced bioprocess automation solutions.
